Impact of REMS on the Health System

Published Online: Tuesday, March 22, 2011
Follow Pharmacy_Times:
In this podcast, Stephen Goldman, MD, talks about the clinical considerations of REMS in health care systems in terms of design, implementation, and management.

Click here to access this third-party resource.
Related Articles
The FDA has granted approval to Genzyme’s eliglustat (Cerdelga), the only first-line oral therapy for patients with Type 1 Gaucher disease.
Grocery store chain joins growing list of major companies offering enhanced specialty pharmacy.
Latest Issues
$auto_registration$